Skip to main content
. 2023 Apr 12;115(7):796–804. doi: 10.1093/jnci/djad061

Figure 2.

Figure 2.

Spectrum of irAEs for cancer patients before (during upfront CD) and after switch to ED, overall and per organ or system involved. CD = canonical interval dosing; ED = extended interval dosing; irAEs = immune-related adverse events.